MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - NOVARTIS
ASTRAZENECA PHARMA vs NOVARTIS - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
NOVARTIS 
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
Current Valuations
| ASTRAZENECA PHARMA | NOVARTIS | ASTRAZENECA PHARMA/ NOVARTIS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 77.0 | 469.8 | 16.4% | View Chart |
| P/BV | x | 21.7 | 27.3 | 79.6% | View Chart |
| Dividend Yield | % | 0.0 | 1.7 | - |
Financials
 ASTRAZENECA PHARMA  NOVARTIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
NOVARTIS Mar-18 |
ASTRAZENECA PHARMA/ NOVARTIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 758 | 168.6% | |
| Low | Rs | 883 | 579 | 152.4% | |
| Sales per share (Unadj.) | Rs | 228.4 | 228.4 | 100.0% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 31.7 | 32.7% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 32.8 | 49.6% | |
| Dividends per share (Unadj.) | Rs | 0 | 10.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.5 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 297.1 | 33.2% | |
| Shares outstanding (eoy) | m | 25.00 | 24.69 | 101.3% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 2.9 | 161.6% | |
| Avg P/E ratio | x | 104.2 | 21.1 | 494.9% | |
| P/CF ratio (eoy) | x | 66.4 | 20.4 | 325.6% | |
| Price / Book Value ratio | x | 10.9 | 2.2 | 486.2% | |
| Dividend payout | % | 0 | 31.5 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 16,505 | 163.6% | |
| No. of employees | `000 | 1.4 | 0.7 | 203.0% | |
| Total wages/salary | Rs m | 1,535 | 1,445 | 106.2% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 8,441.3 | 49.9% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 2,163.6 | 52.3% | |
| Avg. net profit/employee | Rs Th | 191.1 | 1,173.1 | 16.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 5,639 | 101.3% | |
| Other income | Rs m | 123 | 1,718 | 7.1% | |
| Total revenues | Rs m | 5,833 | 7,357 | 79.3% | |
| Gross profit | Rs m | 463 | -63 | -740.6% | |
| Depreciation | Rs m | 147 | 25 | 582.6% | |
| Interest | Rs m | 0 | 55 | 0.0% | |
| Profit before tax | Rs m | 438 | 1,575 | 27.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 792 | 22.6% | |
| Profit after tax | Rs m | 259 | 784 | 33.1% | |
| Gross profit margin | % | 8.1 | -1.1 | -731.4% | |
| Effective tax rate | % | 40.8 | 50.3 | 81.3% | |
| Net profit margin | % | 4.5 | 13.9 | 32.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 9,522 | 33.7% | |
| Current liabilities | Rs m | 2,070 | 3,296 | 62.8% | |
| Net working cap to sales | % | 20.0 | 110.4 | 18.1% | |
| Current ratio | x | 1.6 | 2.9 | 53.7% | |
| Inventory Days | Days | 72 | 37 | 197.6% | |
| Debtors Days | Days | 35 | 28 | 122.9% | |
| Net fixed assets | Rs m | 790 | 46 | 1,718.0% | |
| Share capital | Rs m | 50 | 123 | 40.5% | |
| "Free" reserves | Rs m | 2,419 | 7,213 | 33.5% | |
| Net worth | Rs m | 2,469 | 7,336 | 33.7% | |
| Long term debt | Rs m | 0 | 0 | - | |
| Total assets | Rs m | 4,605 | 11,105 | 41.5% | |
| Interest coverage | x | NM | 29.5 | - | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 1.2 | 0.5 | 244.2% | |
| Return on assets | % | 5.6 | 7.6 | 74.5% | |
| Return on equity | % | 10.5 | 10.7 | 98.2% | |
| Return on capital | % | 17.7 | 22.2 | 79.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 61 | 494.3% | |
| Fx outflow | Rs m | 2,015 | 3,630 | 55.5% | |
| Net fx | Rs m | -1,715 | -3,570 | 48.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 1,610 | 5.5% | |
| From Investments | Rs m | -94 | 687 | -13.6% | |
| From Financial Activity | Rs m | NA | -2,677 | 0.0% | |
| Net Cashflow | Rs m | -6 | -380 | 1.5% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 75.0 | 75.0 | 100.0% | |
| Indian inst/Mut Fund | % | 0.3 | 2.0 | 15.0% | |
| FIIs | % | 15.7 | 1.6 | 981.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 21.5 | 42.3% | |
| Shareholders | 12,856 | 41,647 | 30.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: WYETH LTD IPCA LABS ALKEM LABORATORIES SUN PHARMA PIRAMAL ENTERPRISES
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)
Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.
Related Views on News
ASTRAZENECA PHARMA Surges by 7%; BSE HEALTHCARE Index Up 0.3% (Market Updates)
Oct 16, 2019 | Updated on Oct 16, 2019ASTRAZENECA PHARMA share price has surged by 7% and its current market price is Rs 2,284. The BSE HEALTHCARE is up by 0.3%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 7.0%). The top losers are LAURUS LABS LTD (down 0.1%) and PIRAMAL ENTERPRISES (down 0.1%).
NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
Rebound Riches Could be Yours With These Stocks(Profit Hunter)
Oct 4, 2019The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.
The One Stock I Like in this Market(The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
MoreASTRAZENECA PHARMA SHARE PRICE
Oct 16, 2019 01:17 PM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - LUPIN COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.